Ontology highlight
ABSTRACT:
SUBMITTER: Yoo S
PROVIDER: S-EPMC4916061 | biostudies-literature | 2016 Jun
REPOSITORIES: biostudies-literature
Yoo Sangjun S Choi Se Young SY You Dalsan D Kim Choung-Soo CS
Prostate international 20160517 2
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including ab ...[more]